Investor Presentaiton
Investor presentation
First three months of 2017
Slide 96
Novo Eight® is launched in the US, Europe and Japan for the
treatment of people with haemophilia A
Example from Novo Eight®
promotional campaign¹
Novo Eight® properties and launch performance
Indications:
.
Treatment and prophylaxis of bleeding in patients with
congenital factor VIII deficiency for all age groups²
Key product characteristics:
•
Reliability: No inhibitor development in PTPs in one of the
largest pivotal trial programmes of any approved rFVIII
(n=213)2,3
• Purity and safety: First rFVIII to use a 20nm filter in its
purification process
• Portability: Room temperature stability with storage at 30
degrees celsius²
Launch status:
•
Novo Eight® is available in the US, EU, Japan
Regulatory approval in 43 countries
•
Commercial or technical launch in 26 countries
1 Picture is not intended for promotional purposes
changing
diabetes®
2 NovoEight® Summary of Product Characteristics. 3 Iorio A et al., Blood 2012; 120(4):
720
727. NovoEight® Prescribing Information
PTP: Previously treated patient
novo nordiskView entire presentation